Elicera Therapeutics (Q2 review): Progress in CARMA-study - Redeye
Bildkälla: Stockfoto

Elicera Therapeutics (Q2 review): Progress in CARMA-study - Redeye

Redeye returns with an update following Elicera's Q2 report and recent events in the company, including a new CEO and data from the CARMA-study with ELC-301. Elicera Screens "attractively priced" in our new market edge system.

Redeye returns with an update following Elicera's Q2 report and recent events in the company, including a new CEO and data from the CARMA-study with ELC-301. Elicera Screens "attractively priced" in our new market edge system.
Börsvärldens nyhetsbrev